JBIO

Jade Biosciences, Inc.

Jade Biosciences, Inc. (JBIO) has 5 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Feb 13, 2026.

  • Industry:Biotechnology
  • CEO:Tom Frohlich
  • Employees:55
  • HQ:Waltham, MA, US
  • IPO:2021-06-30

No open-market insider trades for JBIO (Jade Biosciences, Inc.) in the last 365 days.

Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.

Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.

See all Form 4 filings on SEC EDGAR ↗

Related companies

Jade Biosciences, Inc. is in the Healthcare sector.